{"id":450573,"date":"2021-03-04T08:03:36","date_gmt":"2021-03-04T13:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450573"},"modified":"2021-03-04T08:03:36","modified_gmt":"2021-03-04T13:03:36","slug":"oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/","title":{"rendered":"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, March  04, 2021  (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021. Oncternal\u2019s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company\u2019s financial results and provide a comprehensive business update.<\/p>\n<p>The live webcast of the call will be available online via a link from the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sBeWZAhdMxz316zsfb5oSnfaAj4RYTTI0DCJUHt9qgLfEdUbafqKuRXKitr2srW2yBHc0K4o2afrmIhcp1WG856jPN1Wgnvk5k8aicFWWPDjD64fcyXs_Z_9vYG2ne8V\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>investor relations page<\/u><\/a> of the Company\u2019s website at www.oncternal.com, and the call will be archived there for at least 30 days.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <strong>About Oncternal Therapeutics<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p>Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab<u>,<\/u> an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1\/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.<\/p>\n<p>\n        <strong><br \/>\n          <strong>Oncternal Contacts:<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Richard Vincent <br \/>858-434-1113<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8PT58Db5Rdhr0Sa_tw74j3NEVW3Lvs-1XP0MAN9UoNSZQJopCc1x_tsJBqHKi9BadBseY49nU5XZn2y2VhAkTNrpkPlqu5tC86Hs81li-zM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rvincent@oncternal.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>212-915-2577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJBBeOgC6C2gdmnLCd1NsHy3EOZzLaL7muYtFMIt-8K2exJ3QmSE9ekfMjEXxmx9v-Exoe7GkzgAaRUigSjl8oDBmX-o0WAbpFnkYtUfaDS65p99kkRl42XX1TDNJ7AX\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a>\u00a0<\/p>\n<p>Source: Oncternal Therapeutics, Inc.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8f189c32-1aae-431f-a748-a7043c273f88\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021. Oncternal\u2019s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company\u2019s financial results and provide a comprehensive business update. The live webcast of the call will be available online via a link from the investor relations page of the Company\u2019s website at www.oncternal.com, and the call will be archived there for at least 30 days.\u00a0 About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450573","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021. Oncternal\u2019s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company\u2019s financial results and provide a comprehensive business update. The live webcast of the call will be available online via a link from the investor relations page of the Company\u2019s website at www.oncternal.com, and the call will be archived there for at least 30 days.\u00a0 About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical &hellip; Continue reading &quot;Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T13:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update\",\"datePublished\":\"2021-03-04T13:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/\",\"name\":\"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==\",\"datePublished\":\"2021-03-04T13:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update - Market Newsdesk","og_description":"SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021. Oncternal\u2019s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company\u2019s financial results and provide a comprehensive business update. The live webcast of the call will be available online via a link from the investor relations page of the Company\u2019s website at www.oncternal.com, and the call will be archived there for at least 30 days.\u00a0 About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical &hellip; Continue reading \"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T13:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update","datePublished":"2021-03-04T13:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/"},"wordCount":353,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/","name":"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==","datePublished":"2021-03-04T13:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzk0OSM0MDQ3MTIxIzUwMDA3NDE2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-report-fourth-quarter-2020-financial-results-and-provide-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450573"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450573\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}